CostrymCostrym
Book a meeting
The asset class no one could access. Until now.

Invest in the best asset class in crypto.

Drug programs are the most profitable asset class in the world. However, most have already consumed hundreds of millions and are stalled due to inefficient execution. We resurrect them with AI-powered reanalysis and tokenize the entire program, so anyone can invest on-chain.

Get started
The numbers
  • $1.5TGlobal drug development market
  • USDCMilestone payouts on-chain
  • LockedMinimum exit price set on day one
  • 12–24moCapital commitment to potential approval
  • One SPVOne program · full transparency
02The Numbers

Drug development is notoriously high-yield. Costrym doubles it with drugs past proof of concept.

Every program on the platform has cleared trials with hundreds of millions already spent. The biology has been tested in humans. Our AI-powered reanalysis identifies the specific, addressable reason it didn't cross the line — bad CRO execution, sub-optimal endpoint, wrong subgroup — and maps the redesigned path to approval. You are not funding a hypothesis. You are funding a resurrection with an existing evidence base.

$100M+
Already spent before we touch a program
Human
Clinical data already exists on every asset
AI
Reanalysis isolates the addressable failure
On-chain
Liquid · traceable · milestone-paid

IP protected for decades. Market is global. Demand is inelastic. People will always need medicine.

The structure didn't exist. Until now.

03Why Drug Development Programs

Most drug investment is a bet on the unknown. Costrym programs are different.

Every program on the platform has already been through clinical trials. Human data exists. The biology has been tested.

These are drugs that have already consumed hundreds of millions of dollars and failed — not from bad science, but from CRO inefficiency and mismanaged execution. Costrym's validation process identifies the specific, addressable reason the program didn't cross the line and maps the redesigned path to approval.

You are not funding a blank slate. You are investing in a program with an existing clinical evidence base, a diagnosed improvement, and a clear path forward.

The information advantage
  • Typical biotech investment
    Bet on the unknown

    An untested molecule. A hypothesis. Years of uncertainty before a single human data point exists.

  • A Costrym program
    Bet on a diagnosed problem

    Existing clinical evidence base, a specific addressable failure point, and a redesigned path to approval.

Hundreds of millions already spent on the science. You invest in the diagnosed correction.

The information advantage no early-stage biotech can offer.

04What Makes This Different

Most RWAs are illiquid, opaque, and lag reality. Costrym is built differently.

Other RWAsLocked & lagging

The standard problem.

  • Illiquid — locked behind fund structures with no exit path
  • Opaque — quarterly reporting that lags reality by 90 days
  • No validation — investors carry diligence risk themselves
  • Payouts only at the end — capital tied up for years with no checkpoints
CostrymOne program · one SPV

Liquid, traceable, validated.

  • Liquid — tokens tradeable on regulated secondary markets between accredited investors
  • Traceable — every transfer, milestone verification, and USDC payout is on-chain and permanent
  • Validated — every program clears full clinical and regulatory review before reaching investors
  • Paid at every checkpoint — USDC distributes automatically at each verified milestone

Your floor is set before capital is committed. No renegotiation. No discretion. No surprises at the finish line. The upside is open.

Minimum exit price locked on day one.

05The Costrym Edge

You invest after the work is done. Not before.

If a program doesn't meet the bar, it doesn't reach the platform. This is the institutional due diligence process — applied before capital is committed, not after.

It is the same information advantage that specialist pharma funds have charged 2-and-20 for. On Costrym, it is built into every deal.

  • 01
    Pre-clinical cleared

    Every program has passed the most risky phase before reaching the platform

  • 02
    Clinical data review

    Prior trial data is reviewed in full before any program is offered

  • 03
    Path to approval

    The program's regulatory path is mapped before a single offer is made

  • 04
    Detailed performance research

    Prior performance is reviewed for maximum due diligence

06How It Works

Four steps from access to payout. Verified programs, USDC at every checkpoint.

  1. 01ApplyVerify accreditation
  2. 02ReviewFull program breakdown
  3. 03InvestBuy program tokens
  4. 04Get paidUSDC at each milestone
Stage 01 / 04
01
Accredited investor verification
Step 01 — Apply·Apply

Submit your details and verify accreditation.

After accredited investor verification you receive access to the investor portal — active programs, full program summaries, milestone schedules, and SPV terms.

One program. Complete transparency.

Not a fund. Not a basket. One asset, one SPV, full visibility into every term and every milestone from the moment you invest until the moment you exit.

07Who This Is For · FAQ

On-chain capital, meet real-world yield.

You have on-chain capital looking for real yield from real assets. You understand SPV structures. You are an accredited investor who can hold a position for a 12–24 month window.

The institutional world has allocated to drug development programs for decades. You now have the same access — same information quality at entry — liquid, on-chain, and with terms locked before you invest.

  • Real estate yields 4–8%. Treasury-backed RWAs yield 5–6%. Drug development programs — with IP protection, global demand, and inelastic markets — operate in a completely different return category. Institutions have known this for decades. The only thing that changed is access.

  • Every program goes through a full clinical data review before it reaches investors. The signal is confirmed, the path to approval is mapped, and terms are structured before capital is raised. If the program doesn't pass validation, it doesn't reach the platform. This is the due diligence step that institutional pharma funds have historically kept proprietary.

  • A single-program SPV tied to one specific drug development program. Your tokens represent your economic interest in that SPV — milestone USDC payouts as the program progresses and a pre-agreed minimum exit price on approval.

  • Yes. Tokens are tradeable on regulated secondary markets between accredited investors. Every transfer is traceable on-chain. This is not a locked fund with no exit path. Liquidity is built into the structure from day one.

  • You keep every milestone payout already distributed. Capital beyond what was returned through milestones is at risk of total loss. This is disclosed in full before any commitment is made.

  • At each verified program milestone — enrollment completion, interim readout, safety review, final endpoint. Payouts are automatic. No discretion. No delays.

  • 12–24 months from capital commitment to potential approval depending on program. Milestone payouts begin distributing during the program — not at the end.

  • Yes. Tokens represent economic interests in an SPV and are structured as securities under US law. Offered exclusively to accredited investors under SEC Regulation D Rule 506(c). Costrym does not operate in jurisdictions where such offerings are prohibited.

  • Apply to gain investor portal access. Accredited investor verification is required before deal materials are shared. Deal flow is not public.

08Investor Terms · Get Started

Same SPV. Same terms. Whether you write a $100 ticket or a nine-figure allocation.

Investor Terms
#COSTRYM / SPV
Structure
One SPV
one program · full visibility

Every program lives in its own single-asset SPV. Buy a single token from your phone, or wire institutional size — the terms, milestones, and on-chain receipts are identical. No tiers, no preferred classes, no hidden allocations.

What you get
  • Milestone USDC payouts at every checkpointIncluded
  • Minimum exit price locked on day oneIncluded
  • Liquid tokens on regulated secondary marketsIncluded
  • Full on-chain traceability — every term, every payoutIncluded
EligibilityReg D 506(c)
Retail accredited
from $100
Single-token entry. Same SPV.
Family offices · funds
$1M – $50M
Direct allocation. Custodied tokens.
Pharma · institutional
Bespoke
Strategic sizing on request.

The asset class that built dynasties — finally written so a single token, or a nine-figure allocation, reads from the same line.

Book a 15-min intro